Publications by the researcher in collaboration with Reyes Bernabé-Caro (15)

2024

  1. Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

    Clinical Drug Investigation, Vol. 44, Núm. 8, pp. 553-576

  2. Family history of cancer and lung cancer: Utility of big data and artificial intelligence for exploring the role of genetic risk

    Lung Cancer, Vol. 195

  3. Multidisciplinary approach for locally advanced non-small cell lung cancer (NSCLC): 2023 expert consensus of the Spanish Lung Cancer Group GECP

    Clinical and Translational Oncology, Vol. 26, Núm. 7, pp. 1647-1663

2022

  1. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Annals of Oncology, Vol. 33, Núm. 2, pp. 181-192

  2. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program

    Oncotarget, Vol. 13, Núm. 1, pp. 812-827

  3. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

  4. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Journal for immunotherapy of cancer, Vol. 10, Núm. 9

2021

  1. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    The Lancet Oncology, Vol. 21, Núm. 11, pp. 1413-1422

  2. Sex is a strong prognostic factor in stage IV non-small-cell lung cancer patients and should be considered in survival rate estimation

    Cancer Epidemiology, Vol. 67

2019

  1. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

    Lung Cancer, Vol. 134, pp. 72-78

  2. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping

    Annals of Oncology, Vol. 30, Núm. 2, pp. 290-296

  3. Lung cancer in Spain: Information from the Thoracic Tumors Registry (TTR study)

    Translational Lung Cancer Research, Vol. 8, Núm. 4, pp. 461-475

2015

  1. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015

    Clinical and Translational Oncology, Vol. 17, Núm. 12, pp. 1020-1029

2012

  1. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial

    The Lancet Oncology, Vol. 13, Núm. 3, pp. 239-246